Covered recipient · General Payments record
VAHAN MADATOVIAN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2025
$4,591.59
- Reported across 193 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $477.73 | 17 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ardelyx, Inc. | $194.02 | 6 |
| Amgen Inc. | $108.09 | 4 |
| ABBVIE INC. | $80.93 | 3 |
| Novo Nordisk AS | $41.45 | 2 |
| Regeneron Healthcare Solutions, Inc. | $33.57 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.61 | 09/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202343373 | CMS |
| ABBVIE INC. | $23.81 | 10/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202343375 | CMS |
| ABBVIE INC. | $31.51 | 11/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202343377 | CMS |
| Amgen Inc. | $32.95 | 03/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228290431 | CMS |
| Amgen Inc. | $34.99 | 04/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228290433 | CMS |
| Amgen Inc. | $14.25 | 12/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227101824 | CMS |
| Amgen Inc. | $25.90 | 12/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228290429 | CMS |
| Ardelyx, Inc. | $30.04 | 02/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247864524 | CMS |
| Ardelyx, Inc. | $29.77 | 03/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247864526 | CMS |
| Ardelyx, Inc. | $29.86 | 06/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247864528 | CMS |
| Ardelyx, Inc. | $34.91 | 07/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247864530 | CMS |
| Ardelyx, Inc. | $34.64 | 08/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247864532 | CMS |
| Ardelyx, Inc. | $34.80 | 12/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247864534 | CMS |
| Novo Nordisk Inc | $17.05 | 01/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188221171 | CMS |
| Novo Nordisk Inc | $24.40 | 02/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188446243 | CMS |
| Regeneron Healthcare Solutions, Inc. | $33.57 | 08/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1212979977 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.67 | 05/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1232016656 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.